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The ambulatory arterial stiffness index (AASI) is a marker of arterial stiffness and is derived 
from ambulatory 24-h blood pressure registration. We studied whether the AASI could 
be used as a predictive factor for the presence of renal artery stenosis (RAS) in patients 
with a suspicion of secondary hypertension and as such as a diagnostic tool for RAS. 
We included 169 patients with difficult-to-treat hypertension. They all underwent 24-h 
ambulatory blood pressure monitoring registration, imaging of the renal arteries, and car-
diovascular risk measurement, including smoking, history, biometrics, blood pressure, 
renal function, lipids, and glucose metabolism. Performing univariate and multivariate 
analyses, we investigated if AASI and the other cardiovascular risk factors were related 
to the presence of RAS. Of the 169 patients (49% women), 31% had RAS. The mean 
AASI was 0.44 (0.16). The presence of RAS showed no significant correlation with AASI 
(r = 0.14, P = 0.06). Age (r = 0.19, P = 0.01), hypercholesterolemia (r = 0.26, P = 0.001), 
history of CVD (r = 0.22, P = 0.004), and creatinine clearance (r = −0.34, P < 0.001) all 
demonstrated a correlation with RAS. Although AASI is higher in patients with RAS, AASI 
does not independently predict the presence of RAS in hypertensive subjects.
Keywords: hypertension, renal artery, atherosclerosis, arterial stiffness, diagnosis, differential, difficult-to-treat 
hypertension, secondary hypertension
introdUCtion
Increased arterial stiffness results from reduced elasticity of the arterial wall and is an independent 
predictor for cardiovascular risk. The ambulatory arterial stiffness index (AASI) is an indirect arterial 
stiffness index, which can be simply calculated from 24-h ambulatory blood pressure monitoring 
(ABPM) and has proven to be associated with cardiovascular adverse events and vascular damage, 
over and beyond 24-h pulse pressure and mean arterial pressure (1–3).
Hypertension is one of the major causes in the development of atherosclerotic vascular and organ 
damage and decline in renal function. Increasing arterial stiffness is a forerunner and early sign of 
atherosclerotic disease and is associated with and a consequence of hypertension (4). Atherosclerotic 
renal artery stenosis (RAS) contributes to the development of hypertension, but atherosclerotic RAS 
in itself is also an important contributing factor in the development of atherosclerotic complications 
apart from the accompanying hypertension (5).
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Therefore, it can be hypothesized that arterial stiffness might 
be higher in the case of concomitant hypertension and RAS than 
in the case of hypertension without RAS. If this proves to be so, 
it could be used to distinguish patients with RAS from those 
without it. The arterial stiffness index could possibly aid in the 
detection and diagnosis of RAS. In treating hypertensive patients, 
it can have implications to know whether or not a renal arterial 
obstruction is present, and it might be valuable to look for this 
condition, therefore, particularly in cases of hypertension that 
are difficult to treat. In such cases, it is advisable to choose the 
least invasive screening option. As the AASI is derived from an 
ABPM that can be obtained without too much inconvenience to 
patients, it could be a real step forward if the AASI could be used 
in this respect.
Therefore, we studied whether the AASI is associated with the 
presence of RAS in patients with hypertension and the clinical 
suspicion of secondary hypertension, more in particular of the 
presence of atherosclerotic RAS. RAS caused by fibromuscular 
dysplasia (FMD) is much less common, has a distinct pathophysi-
ology, and is not a subject of this study.
patients and MetHods
We included 169 consecutive patients with a clinical suspicion 
of secondary hypertension mainly based on difficult-to-treat 
hypertension indicated by a persistent blood pressure over 
140/90 mmHg, who were referred to our tertiary hypertension 
unit. The study was retrospective in nature, and we used a 
 pre-specified protocol. All included patients underwent imaging 
of the renal arteries and 24-h ABPM. Patients were excluded if 
they were diagnosed with a parenchymal renal disease other than 
that caused by atherosclerotic or hypertensive changes. Subjects 
with diabetic nephropathy with proteinuria >1.0 g/day were also 
excluded.
ethical Considerations
This study was retrospective in nature and had no effect on the 
treatment of patients who enrolled. No experimental investiga-
tions were done, and all data were obtained in the course of usual 
patient care management. The data were completely de-identified. 
According to the guidelines of the institutional ethics board, it was 
not necessary, therefore, to obtain written informed consent of all 
patients. All conditions of the latest version of the Declaration of 
Helsinki of the World Medical Association were met.
Measurement of ras
State-of-the-art transcatheter angiographies [intra-arterial (i.a.) 
TCA], CT angiographies (CTA), or magnetic resonance angiog-
raphies (MRA) of the renal arteries were made in all patients. The 
state-of-the-art MRA and CTA result in reliable estimates of renal 
artery obstruction in comparison to i.a. TCA (6). If there was a 
high suspicion of FMD, primarily an i.a. TCA was done. If there 
was any doubt in interpreting the lesions found on CTA or MRA, 
an i.a TCA was made.
Each renal artery was analyzed for the presence of stenosis, 
which was graded on the basis of the most severe reduction of 
arterial diameter compared with an uninvolved renal artery 
segment proximal or distal to the stenosis. A renal artery was 
graded as normal if no luminal obstruction was present. A ste-
nosis was considered high-grade if it was over 50% of luminal 
surface and low-grade if it was under 50% of luminal surface.
According to the radiological reports, which were conducted 
by radiologists experienced in this field, subjects were classified 
into three groups as (1) having no RAS, (2) having low-grade 
RAS (<50%), and (3) having at least one high-grade RAS (>50%). 
Baseline and follow-up clinical and biochemical data were gath-
ered through a pre-specified protocol. The angiographies and the 
ABPM measurements were done during the initial work-up of the 
patients after referral to our institution.
Blood pressure Measurements
Hypertension was defined according to European guidelines as 
conventional systolic blood pressure (SBP) ≥140  mmHg and/
or diastolic blood pressure (DBP) ≥90  mmHg. Experienced 
clinicians measured conventional blood pressure by comput-
ing the mean of three blood pressure recordings after resting 
10 min in the semi-supine position, with the cuff placed at the 
level of the heart and patients’ legs uncrossed. ABPM recordings 
were programed at 15–30-min intervals during daytime and at 
 30–60-min intervals during nighttime. ABPM quality criteria 
included an interval range of 15 min, with at least five readings 
between midnight and 0600 hours and at least 15 daytime read-
ings (7). If these criteria were not met, patients were excluded. 
The validated monitors used, were the oscillometric SpaceLabs 
90207 (SpaceLabs Inc., Redmond, Washington, DC, USA), the 
Oxford Medilog (Oxford Medical Systems Ltd., Oxford, UK), and 
the oscillometric Mobil-O-Graph (I.E.M., Stolberg, Germany).
The regression slope of diastolic on SBP was computed from 
the 24-h ABPM recordings. AASI was defined as one minus the 
regression slope (8). We used the coefficient of determination (r2) 
as a measure of goodness of fit of the AASI regression line (9).
other Measurements
We used the questionnaires originally administered to obtain 
information on each subject’s medical history and smoking and 
drinking habits. The following data were also retrieved: age, sex, 
height, weight, body mass index (BMI, the weight in kilograms 
divided by the square of the height in meters), duration of hyper-
tension, and the number of antihypertensive drugs. Hypertensive 
patients received antihypertensive drugs with a diastolic target 
BP ≤90 mmHg and systolic <140 mmHg or lower according to 
comorbid conditions (10).
Renal function was measured by estimating creatinine clear-
ance, using the Cockroft–Gault formula (11). Renal failure was 
defined as proteinuria (defined as urinary protein in concentra-
tions greater than 0.3 g in a 24-h urine collection) or a glomerular 
filtration rate of less than 90 mL/min/1.73 m2. End-stage renal 
failure was defined as a glomerular filtration rate of less than 
15 mL/min/1.73 m2.
We measured serum cholesterol and blood glucose by auto-
mated enzymatic methods. Hypercholesterolemia was defined as 
a serum total cholesterol level of ≥5.2 mmol/L or the intake of 
lipid-lowering drugs. Diabetes mellitus type was a self-reported 
diagnosis, or a fasting or random blood glucose level of at least 
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7.0 mmol/L (126 mg/dL) or 11.1 mmol/L (200 mg/dL), respec-
tively, or the use of anti-diabetic drugs. Presence of cardiovascular 
disease (CVD) was defined as a medical history with coronary 
artery disease (defined as ischemic changes on exercise tolerance 
testing or by significant obstruction on coronary angiography), 
myocardial infarction, transient ischemic attack, ischemic stroke 
or death from any cardiovascular cause, peripheral arterial dis-
ease, or vascular surgery.
statistiCaL anaLysis
For statistical analysis and database management, we used SPSS 
v.22 for Windows (SPSS Inc., Chicago, IL, USA). We compared 
means and proportions by ANOVA and the χ2 statistic, respec-
tively, and evaluated unadjusted associations with Pearson’s 
correlation coefficient. To evaluate the association between AASI 
and RAS, we calculated unadjusted, age- and sex-adjusted and 
multivariable-adjusted odds ratios (ORs) plus 95% confidence 
intervals (CIs), with the study subgroup without RAS set as the 
reference group. In regression analysis, we adjusted for selected 
baseline characteristics that are known to increase risk of RAS, 
including sex, age, BMI, current smoking, diabetes mellitus, 
hypercholesterolemia, previous CVD, and family history of CVD.
resULts
patient Characteristics
The 169 participants included 83 females (49.1%). Blood-
pressure-lowering drugs at the time of referral were used by 154 
(91.1%) of the patients. This medication had been stopped in 
a few patients because of insufficient effect before referral. The 
number of different antihypertensive medications per patient was 
2.3 ± 1.3. Mean (±SD) age was 48.0 ± 13.5 years.
At enrollment, 66 participants (39.1%) were current smokers; 
61 (36.1%) reported intake of alcohol; 89 (52.7%) reported a his-
tory of CVD; 54 (32.0%) showed hypercholesterolemia or were 
treated for it; 25 (14.8%) had diabetes mellitus; and 14 (8.3%) had 
renal insufficiency, 1 of whom had end-stage renal failure.
In the whole study population, the mean (±SD) 24-h blood 
pressure averaged 152.4 ± 20.0 mmHg SBP and 94.3 ± 13.8 mmHg 
DBP. The 24-h mean (±SD) arterial pressure averaged 
114.8 ± 15.0 mmHg. The mean heart rate was 73.1 ± 13.6 bpm. 
The mean (±SD) AASI was 0.44 ± 0.16.
An i.a. TCA of the renal arteries was obtained in 129, a CTA 
in 21, and an MRA in 29 patients. RAS was diagnosed in 52 
participants (30.8%), 32 (18.9%) of whom had severe RAS with 
a luminal obstruction over 50%, and 7 (4.1%) of the entire group 
with a stenosis had bilateral RAS over 50%. Table 1 lists the main 
clinical characteristics of subjects with and without RAS.
Unadjusted analysis
Both groups included nearly 50% women. Subjects with RAS 
were older (51.8 versus 46.3, P = 0.01), had a marginally lower 
BMI (26.6 versus 27.8  kg/m2, P =  0.17), and more often had 
hypercholesterolemia (48 versus 24%, P <  0.001), a history of 
CVD (69 versus 45%, P = 0.004) or renal failure (12 versus 7%, 
P =  0.31) with an average creatinine clearance of 84.9 versus 
108.7 mL/min (P < 0.001). The AASI in patients with RAS versus 
without RAS was 0.48 ± 0.15 (CI ±0.03 range 0.40–0.46) versus 
0.43 ± 0.17 (CI 0.05 range 0.43–0.53) (P = 0.06) (Figure 1). In 
the RAS group, the seven patients with a bilateral significant RAS 
had the highest mean AASI of 0.56. Further separate analysis of 
this small group is not meaningful.
Multivariable analysis
In all 52 subjects, RAS was independently associated with creati-
nine clearance with an OR of 20.49 (P < 0.001) (Table 2). RAS 
was not independently associated with AASI, age and history of 
CVD, whereas the association with non-HDL cholesterol was 
borderline significant (OR 3.53, P = 0.06).
disCUssion
In this study population, the AASI was not independently asso-
ciated with the presence of RAS in patients with a suspicion of 
secondary hypertension. In the univariate analysis, higher age, 
lower creatinine clearance, hypercholesterolemia, and history of 
CVD were associated with RAS, whereas only lower creatinine 
clearance was independently associated with RAS.
Renal artery stenosis carries a high risk for cardiovascular 
complications and is associated with increasing mortality. Even 
low-grade RAS, defined as RAS <50% of the arterial lumen, is 
associated with future cardiovascular events (12). Therefore, it 
is important to be able to identify patients suffering from this 
condition. In the search for secondary hypertension, the diag-
nostic evaluation of hypertensive patients is challenging because 
multiple requirements have to be fulfilled. Ideally, a screening 
technique should be accurate, reliable, non-invasive, and not 
prone to complications, as is the case with nephrotoxic contrast 
agents necessary in the definitive diagnosis of RAS. Before turn-
ing to invasive investigations, it would be very useful to identify 
the patients with the greatest risk of this condition, so that the 
number of invasive procedures could be limited.
There are at present several specific clinical and biochemical 
clues that can suggest various forms of secondary hypertension 
(13). If present, these can guide investigations that are sup-
plementary to the routine screening tests. In addition, various 
clinical risk factors can be identified that point to secondary 
hypertension in general without specific clues as to what kind of 
secondary hypertension might be involved (14). These include 
poor response to adequate therapy, worsening of control in 
previously stable blood pressure, age of onset younger than 20 or 
older than 50, and various others (14). It is important to identify 
secondary hypertension because cardiovascular morbidity and 
mortality are determined to a large extent by clinical conditions 
that involve the arterial system.
The presence of atherosclerotic vascular lesions is in itself also 
a very strong indicator of cardiovascular morbidity and mortality 
(15). The presence of an atherosclerotic RAS, even a less than 50% 
stenosis, is accompanied by a high risk of cardiovascular compli-
cations as compared to hypertension without RAS (8, 13, 16–18). 
A cohort of patients with RAS, detected at the time of coronary 
angiography, showed a 4-year survival rate of 65% as opposed 
to 86% for those without RAS (16). Most patients with RAS 
FigUre 1 | ambulatory arterial stiffness index stratified for the presence of renal artery stenosis (ras). A boxplot is shown with median and upper and 
lower quartiles. The P-value between groups is 0.06. No stenosis indicates the patients with no RAS. Stenosis indicates the patients without a RAS.
taBLe 1 | Baseline characteristics of participants categorized by renal artery stenosis (ras).
all no ras ras P-value
ras versus no ras
Number of patients (% women) 169 (49) 117 (50) 52 (46) 0.61
Age (years) 48.0 (±13.5) 46.3 (±13.5) 51.8 (±12.8) 0.01
BMI (kg/m2) 27.4 (±5.0) 27.8 (±5.1) 26.6 (±4.9) 0.17
Height (cm) 170.3 (±9.8) 171.0 (±10.5) 168.8 (±9.0) 0.18
Smoking (%) 66 (40) 41 (35) 25 (38) 0.12
Hypercholesterolemia (%) 54 (32) 28 (24) 26 (48) 0.001
LDL cholesterol (mmol/L) 3.3 (±1.1) 3.2 (±1.0) 3.6 (±1.3) 0.10
Non-HDL cholesterol (mmol/L) 4,0 (±1.2) 4,7 (±2.2) 4,2 (±1.5) 0.02
Fasting blood glucose (mmol/L) 5.7 (±1.8) 5.7 (±1.9) 5.7 (±1.6) 0.92
Cardiovascular disorder (%) 89 (53) 53 (45) 36 (69) 0.004
Renal failure (%) 14 (8) 8 (7) 6 (12) 0.31
Creatinine clearance (mL/min) 101.4 (±32.8) 108.7 (±32.2) 84.9 (±28.3) <0.001
Number of antihypertensive drugs 2.3 (±1.3) 2.4 (±1.3) 2.1 (±1.3) 0.29
24-h ambulatory measurements
Systolic pressure (mmHg) 152.4 (±20.0) 151.6 (±18.7) 154.2 (±22.9) 0.44
Diastolic pressure (mmHg) 94.3 (±13.8) 94.8 (±13.7) 93.1 (±13.8) 0.45
Mean arterial pressure (mmHg) 114.8 (±15.0) 114.6 (±14.4) 115.0 (±16.4) 0.87
Heart rate (bpm) 73.1 (±13.6) 73.4 (±12.6) 72.2 (±15.8) 0.62
AASI 0.44 (±0.16) 0.43 (±0.15) 0.48 (±0.17) 0.06
Data are given in mean numbers unless indicated otherwise; ± indicates one SD, % indicates percentage of that group.
RAS, renal artery stenosis; BMI, body mass index; LDL, low density lipoprotein; HDL, high density lipoprotein; AASI, ambulatory arterial stiffness index; bpm, beats per minute.
Creatinine clearance was calculated by the Cockroft–Gault formula.
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also have renal insufficiency in varying severity and diminished 
renal function in general. A decline in renal function is also an 
important independent contributing factor to the development of 
CVD complications (19).
One expression of vascular damage is increased arterial stiff-
ness, which as such is an important marker and predictor of CVD 
complications (15, 16). This parameter is also recognized as a 
marker of subclinical target organ damage.
taBLe 2 | Univariable and multivariable odds ratio (or) models for presence of renal artery stenosis (ras) in 52 hypertensive patients with ras.
Univariable or 95% confidence intervals (Ci) P-value Multivariable or 95% Ci P-value
Male gender 1.19 0.62–2.28 NS
Age 1.03 1.01–1.06 0.02 0.15 0.96–1.03 0.70
Bodymass index 0.95 0.89–1.02 NS
Height 0.09 0.00–3.07 NS
Smoking 1.69 0.87–3.29 NS
Hypercholesterolemia 3.18 1.60–6.34 0.001
LDL cholesterol 1.34 0.94–1.90 NS
Non-HDL cholesterol 1.33 1.01–1.77 0.05 3.53 0.99–1.56 0.06
Fasting blood glucose 1.01 0.83–1.23 NS
Cardiovascular disorder 2.72 1.36–5.43 0.05 2.04 0.85–2.83 0.15
Renal failure 1.78 0.58–5.41 NS
Creatinine clearance 0.97 0.96–0.99 <0.001 20.49 0.96–0.99 <0.001
Number of antihypertensive drugs 0.87 0.67–1.12 NS
24-h ambulatory measurements
Systolic pressure 1.01 0.99–1.02 NS
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Taking these corroborations together, it seemed likely that 
hypertensive patients with RAS would show greater arterial stiff-
ness when compared to those without RAS and that the difference 
might be such that it might be possible to distinguish between 
these groups based on arterial stiffness. We chose the AASI as the 
measure of arterial stiffness because this information is readily 
available from 24-h ABPM, which is regarded as the golden stand-
ard of blood pressure measurement. Several studies confirmed the 
clinical usefulness of the AASI as a measure of arterial stiffness as 
well as its prognostic significance for the appearance of cardiovas-
cular complications in patients with hypertension (1–3, 9, 19, 20).
In the present study, AASI did show an independent relation 
with RAS but only to bilateral RAS and not to unilateral stenosis. 
However, the number of patients with bilateral RAS is too small 
to permit definitive conclusions. Could the number of patients 
overall in this study be too small to detect a significant difference? 
Given the CI of the means and the differences between the two 
groups, it is doubtful whether such a difference is in fact present. 
From the number of patients in this study and the outcomes, 
a power of 0.5 could be calculated. To get a power of 0.8, the 
number of patients in each group would have to be 163.
On the basis of these results of this study, it seems reason-
able to conclude that there is no clinically important difference 
in AASI between these two groups. Almost all patients were on 
hypertensive medication when the ABPM values were obtained. 
A recent study showed convincingly that antihypertensive treat-
ment has only a marginal effect on the AASI over time (21). So, 
the use of medication has certainly not had enough effect to 
distort the results of this study. AASI showed a correlation with 
age, systolic 24-h blood pressure, and 24-h heart rate. There was 
also an independent relation between RAS and higher age, higher 
BMI, raised LDL cholesterol level, lowered GFR, and a history 
of CVD. These are all well-known indicators of severe vascular 
damage and heralds of further CVD complications.
So, the hypertensive patients in this study showed the con-
firmed parameters of advanced vascular disease, but the AASI was 
not one of them, only among those with bilateral stenosis, a group 
known for its high risk of imminent CVD complications (22). The 
AASI and, hence, arterial stiffness did not show an independent 
relation with RAS. This seems contrary to expectations as the 
relation between arterial stiffness and CVD complications is so 
strong (1–3, 9, 19, 20, 23–26).
There are some possible explanations for this. First, the average 
AASI in the group without RAS was 0.43; the average AASI in the 
group with RAS was 0.48; and in the group with bilateral RAS it 
was 0.56. These values are in the highest quintiles, as was shown in 
a study of hypertensive patients (9). Those with an AASI in these 
upper quintiles had the highest risk of CVD complications (9). The 
AASI as an indirect measure of vascular stiffness in patients with 
hypertension with or without a RAS in this study, therefore, are 
already in the highest proportion of this measure. As all groups are 
at an advanced stage of vascular damage with a high degree of arterial 
stiffness, a further significant difference between these patients may 
not be identifiable.
This study was not aimed at directly evaluating whether 
AASI correlates with arterial stiffness, as we performed no 
direct measure of arterial stiffness such as pulse wave velocity. 
We merely studied the relation of an indirect measure of arterial 
stiffness with the presence of a serious atherosclerotic compli-
cation in hypertensive patients. Another matter could be the 
generalizability of the outcome. The patients in this study had 
difficult-to-treat hypertension and other clinical or biochemical 
indicators suggesting secondary hypertension. Since there were 
no other selection criteria for this specific group, they can be 
considered representative for this group of hypertensive patients 
in general (24).
Though we did indeed reveal that hypertensive patients with 
RAS have a mean higher AASI than those without, this difference 
was not large enough to be useful as a distinctive feature. So, in 
this study, we could not find a value of the AASI that indicates 
the presence of RAS. Therefore, we could not advise introducing 
the AASI in the clinical decision-making in hypertensive patients 
suspected of secondary hypertension.
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